Search Browse Earnings

Replimune Group, Inc. — SlamSEC

Replimune Group, Inc.

Nasdaq:REPL

Biological Products, (No Diagnostic Substances)·WOBURN, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$232.1M

FY 2025

Net Income

-$215.8M

FY 2025

EPS (Diluted)

-$3.24

FY 2025

Stock Price

$8.22

+1.9%

2026-03-10

52W Range

$2.68 – $13.24

P/E Ratio

-2.5x

Market Cap

$678.7M

Cash

$74.5M

FY 2025

Total Debt

$44.8M

FY 2025

Net Cash

$29.6M

FY 2025

Enterprise Value

$649.1M

Debt / EBITDA

0.1x

FY 2025

EV / EBITDA

-2.8x

Employees

—

CEO

Patel Sushil

CFO

Hill Emily Luisa